Download full-text PDF

Source
http://dx.doi.org/10.1007/s00266-024-04076-0DOI Listing

Publication Analysis

Top Keywords

letter editor
4
editor promise
4
promise pitfalls
4
pitfalls ai-generated
4
ai-generated anatomical
4
anatomical images-evaluating
4
images-evaluating midjourney
4
midjourney aesthetic
4
aesthetic surgery
4
surgery applications
4

Similar Publications

Bosutinib for the Treatment of CML-Using it Safely: a Podcast.

Target Oncol

January 2025

Division of Hematology and SCT, Georgia Cancer Centre, Augusta, GA, USA.

Bosutinib is a second-generation tyrosine kinase inhibitor (TKI) approved for use in patients with newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase (CP) chronic myeloid leukemia (CML), as well as Ph-positive CP, accelerated phase, or blast phase (with chemotherapy) CML resistant or intolerant to prior therapy. Clinical trials have shown bosutinib is effective as first-line therapy for patients with CML as well as in later lines of therapy after prior TKI failure. Bosutinib has an established safety profile; however, as with all TKIs approved for the treatment of CML, there are adverse events (AEs) that require management.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!